Genmab/AbbVie Look To Encroach On Roche’s Turf With Epkinly Follicular Lymphoma Results

Genmab A/S and AbbVie Inc. are moving quickly to expand the market for their CD20xCD3-directed bispecific antibody, Epkinly (epcoritamab-bysp), with new topline results for the drug in follicular lymphoma (FL) just a month after the drug won accelerated approval from the US Food and Drug Administration for diffuse large B-cell lymphoma (DLBCL). The new data set Epkinly up as a potential competitor to Roche Holding AG’s anti-CD20xCD3 bispecific Lunsumio (mosunetuzumab-axgb), which received an FDA nod late last year.

Genmab and AbbVie announced 27 June topline results from the Phase I/II EPCORE NHL-1 trial testing Epkinly in 128 adults with relapsed/refractory FL who had received at least two prior lines of therapy, more than 70% of whom were double refractory to an anti-CD20 monoclonal antibody – Roche’s Rituxan (rituximab) and its biosimilars are